Andrew Dauber
Pediatric Endocrinology · Cincinnati, OHNPI 1457410813
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Novo Nordisk Health Care AG at 41.6% of the total. Among pediatric endocrinology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $1586.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk Health Care AG$80K
- Biomarin Pharmaceutical Inc.$76K
- Pfizer$15K
- Novo Nordisk$11K
- Ascendis Pharma Endocrinology Inc$4K
- AstraZeneca$2K
- plus $3K from 8 others
Across 641 payments — averaging $8158.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$3.6M
- Pfizer$1.4M
- Novo Nordisk AS$111K
- Neurocrine Biosciences, Inc.$105K
- Novo Nordisk Health Care AG$13K
- Ascendis Pharma Endocrinology Inc$5K
- plus $2K from 1 others
What the payments were for
- Consulting fees$114,28660%
- Speaking & faculty fees$25,64813%
- Travel & lodging$48,69025%
- Food & beverage$3,1602%
- Education$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk Health Care AG | 38 | $79,810 |
| Biomarin Pharmaceutical Inc. | 56 | $76,350 |
| Pfizer | 7 | $15,280 |
| Novo Nordisk | 7 | $10,851 |
| Ascendis Pharma Endocrinology Inc | 1 | $3,925 |
| AstraZeneca | 1 | $2,250 |
| Neurocrine Biosciences, Inc. | 2 | $2,074 |
| OPKO Pharmaceuticals, LLC | 1 | $550 |
| Eton Pharmaceuticals, Inc. | 1 | $500 |
| Soleno Therapeutics, Inc. | 1 | $246 |
| Hexal AG | 3 | $63 |
| Insulet Corporation | 1 | $24 |
| BETA Bionics, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$62,473
- VOXZOGO 1.2mg$37,794
- NGENLA$13,633
- Sogroya$8,779
- Strensiq$2,250
- Rayaldee$550
- Alkindi$500
- KHINDIVI$500
- INCRELEX$500
- VYKAT XR$246
How this compares
$191,961 in reported general payments places this provider in the 95th percentile of 76 pediatric endocrinology providers in Ohio.
Other pediatric endocrinology in Cincinnati
- Philippe BackeljauwCincinnati$632K
- Nana Hawa Yayah JonesCincinnati$92K
- Susan RoseCincinnati$17K
- Iris Gutmark-LittleCincinnati$14K
- Halley WassermanCincinnati$9K
- Amy ShahCincinnati$8K
- Ryan BradyCincinnati$5K
- Nicole SheanonCincinnati$3K
- Deborah ElderCincinnati$2K
- David KleinCincinnati$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.